A Randomized Controlled Study of Mesalamine After Acute Diverticulitis
Authors:
- Neil StollmanNSNeil Stollman
- Simon MagowanSMSimon Magowan
- Fergus ShanahanFSFergus Shanahan
- Eamonn M.M. QuigleyEQEamonn M.M. Quigley
- 1 August 2013
- journal article
- research article
- Published by Wolters Kluwer Health in Journal of Clinical Gastroenterology
- Vol. 47 (7) , 621-629
Abstract
We evaluated the efficacy of mesalamine (Asacol) in reducing gastrointestinal symptoms after an acute attack of diverticulitis. This was a 1-year double-blind, randomized, placebo-controlled study in which patients with computed tomography scan confirmed acute diverticulitis received placebo, mesalamine, or mesalamine+Bifidobacterium infantis 35624 (Align) for 12 weeks and followed for 9 additional months. Efficacy was assessed using a global symptom score (GSS) of 10 symptoms (abdominal pain, abdominal tenderness, nausea/vomiting, bloating, constipation, diarrhea, mucus, urgency, painful straining, and dysuria). Patients were required to have a GSS≥12 at baseline, including an abdominal pain score >2. One hundred seventeen patients (placebo, 41; mesalamine, 40; mesalamine+probiotic, 36) were randomized and treated. GSS decreased in all groups during treatment without a statistically significant difference between mesalamine and placebo, however; scores were consistently lower for mesalamine at all time points. The rate of complete response (GSS=0) was significantly higher with mesalamine than placebo at weeks 6 and 52 (P<0.05), and was particularly high for rectosigmoid symptoms at weeks 6, 12, 26, and 52. Recurrence of diverticulitis was low and comparable across groups. Probiotic in combination with mesalamine did not provide additional efficacy. In the first US randomized placebo-controlled trial of anti-inflammatory treatment after a documented case of diverticulitis, mesalamine demonstrated a consistent trend in reducing symptoms. Addition of probiotic did not increase mesalamine efficacy. This study supports further investigation into the use of anti-inflammatory agents, such as mesalamine, in the long-term management of diverticulitis. ClinicalTrials.gov NCT00554099.Keywords
This publication has 39 references indexed in Scilit:
- Prevention of Complications and Symptomatic Recurrences in Diverticular Disease with Mesalazine: A 12-Month Follow-upDigestive Diseases and Sciences, 2007
- Increased concentration of tissue-degrading matrix metalloproteinases and their inhibitor in complicated diverticular diseaseScandinavian Journal of Gastroenterology, 2007
- Review article: uncomplicated diverticular disease of the colonAlimentary Pharmacology & Therapeutics, 2006
- Efficacy of Mesalazine in the Treatment of Symptomatic Diverticular DiseaseDigestive Diseases and Sciences, 2005
- Acute diverticulitis of the colon – current medical therapeutic managementExpert Opinion on Pharmacotherapy, 2004
- The effect of non-pathogenic Escherichia coli in symptomatic uncomplicated diverticular disease of the colonEuropean Journal of Gastroenterology & Hepatology, 2003
- Twenty-four hour recordings of colonic motility in patients with diverticular diseaseDiseases of the Colon & Rectum, 2001
- Type I and III Collagens in Human Colon Cancer and DiverticulosisScandinavian Journal of Gastroenterology, 2000
- Sigmoid motility in diverticular disease and the irritable bowel syndrome.Gut, 1988
- Elastosis in diverticular disease of the sigmoid colon.Gut, 1985